Real-life Treatment Outcomes of Ravulizumab in PNH
← catalyst calendarNCT06633536 · readout in 713 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
64actual
Sites
11
Country
Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-06 | actual | When the study began enrolling |
| Primary completion | 2028-08-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Paroxysmal Nocturnal Haemoglobinuria
Intervention
- Drug: Ravulizumab
Primary outcomes
what the primary-completion date above is the date OFChange in LDH levels from index date (first dose of ravulizumab) at every 6 month
measured up to 36 months
Proportion of patients achieving or remaining at LDH<1.5 ULN at every 6 month
measured up to 36 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed